Medical Partners Innovation Competition Champions File IPO Prospectus

As the curtain fell on the competition, who would ultimately emerge as the strongest among the strong? On March 19, the “Medical Path to Growth, Collaborative Win-Win” Healthcare Partner Innovation Cooperation Scheme Competition, jointly organized across industries by four leading enterprises—Pfizer China, Ping An Insurance, Tencent, and Legend Capital, and strongly supported by the Bill & Melinda Gates Foundation, WeDoctor Group, DXY, and United Family Healthcare, came to a successful conclusion in Beijing.

Following intense competition at the final roadshow, Mingyi Zhudao and Aier Shidai were awarded the Championship in the Medical Services Category. Tumor Catcher exclusively secured the Championship in the Medical Technology Category. In addition, Tumor Catcher received the Most Publicly Attentive Award; Dana Biotechnology’s novel early rapid combined diagnostic product for invasive fungal diseases (IFD) won the Most Innovative Value Award; and New Horizon Health received the Most Medical Value Award.

Each with Its Own Merits, All “Heroes” of the Era

Fierce competitions inevitably produce both winners and losers; yet in the Medical Partners competition, even those who do not prevail are heroes. In the field of internet healthcare, they have demonstrated the courage to innovate and a willingness to dedicate themselves.

At the final roadshow, the 12 finalist teams each showcased their unique strengths, with projects in both medical services and medical technology demonstrating distinct characteristics.

Medical Services Category

Renowned Physician-Led Surgery

Shanghai Chuangxian Network Technology Co., Ltd.

Mingyi Zhudao is China’s largest mobile surgical healthcare platform, dedicated to providing professional, efficient, and safe surgical medical services to patients in need of surgery, and facilitating appointments with renowned specialists for surgical procedures. Headquartered in Shanghai with branches in multiple cities, its business coverage extends across China. The platform aggregates top-tier medical experts from both domestic and international sources, as well as underutilized hospital bed resources. By leveraging internet technology, it achieves precise matching between patients and physicians, optimizes the allocation of medical resources, and effectively addresses patients’ practical needs for accessible and high-quality medical care.

iEar Era

Beijing Aier Times Education Consulting Co., Ltd.

Ai’er Shidai is China’s largest hearing healthcare platform. Founded in 2013, it is committed to building an international, high-quality brand for hearing healthcare services, integrating superior professional hearing resources both domestically and abroad, and meeting the hearing care needs of individuals with hearing loss in China. Leveraging international training backgrounds and globally recognized credentials, Ai’er Shidai audiologists focus on providing Chinese families with one-stop, comprehensive, and professional hearing solutions.

“Global Imaging” Medical Cloud Service Platform

Hangzhou Lianzhong Medical Technology Co., Ltd.

Hangzhou Lianzhong Medical Technology Co., Ltd. is dedicated to technological advancement and service innovation in the field of internet healthcare. Its independently developed “Global Imaging” medical cloud service platform is built upon large-scale acquisition of medical imaging data, cloud storage, and secure, rapid, standardized transmission of imaging data. The platform meets a range of comprehensive healthcare application needs, including remote consultations between hospitals, two-way patient referrals, and remote patient visits, thereby creating a complete online-to-offline closed loop. This enhances the networked, informatized, and mobile capabilities of healthcare institutions as well as the efficiency of information-based diagnosis and treatment, offering solutions to pressing social issues such as difficult and costly access to medical care, while exploring new models in support of national healthcare reform policies.

Palm Sugar Doctor

Hangzhou Kangsheng Health Management Consulting Co., Ltd.

As a pioneer in the field of diabetes health management services, Zhangshang Tangyi is committed to building China’s largest one-stop management service platform for chronic diseases. By providing scientifically grounded, personalized medical service solutions and leveraging Alibaba Cloud’s big data for precise user engagement, the company has helped nearly one million individuals with diabetes and other chronic conditions improve their self-management and reclaim a healthy new life within just one year.

Mommy Knows

Shenzhen Yixin Technology Co., Ltd.

Mami Zhidao is an online medical consultation platform for mothers and infants, launched by Yixin Technology in 2015. The platform has exclusive contracts with obstetricians and pediatricians from Grade 3A hospitals in key cities across China, providing online waiting rooms and timely responses to address health concerns for both mothers and babies. Additionally, Mami Zhidao insists on original content created by doctors, offering a vast amount of popular science information to help mothers comprehensively master parenting skills. Mami Zhidao enables mothers to consult doctors from the comfort of their homes without having to step outside.

Gairui Technology

Beijing Gairui Technology Co., Ltd.

Gairui Technology is a high-tech enterprise specializing in the research and development, sales, value-added business management, and operation of mobile medical products. Leveraging its outstanding capabilities in medical product R&D and deep technical reserves in the mobile internet sector, the company has successfully built comprehensive healthcare and health management solutions—covering health tracking, chronic disease management, and telemedicine services—within two key areas: tiered diagnosis and treatment at the primary care level, and personal health management services. By deploying its business through Micro-Testing and Cloud Consultation, it has established an online cloud platform alongside offline Micro-Testing Centers. Currently, its services extend to nearly 20 provinces across China, making it a leading provider of mobile medical services and solutions in the country.

Medical Technology

“Tumor Catcher” – Peptide Nanomagnetic Bead Technology for Detecting Circulating Tumor Cells (CTCs) in Peripheral Blood

Beijing Zhongke Natai Biotechnology Co., Ltd.

Zhongke Natai is a nanobiotechnology company dedicated to advancing liquid biopsy technologies. Leveraging the scientific research strengths of the National Center for Nanoscience and Technology, Chinese Academy of Sciences, and building on nanotechnology platforms characterized by “high-throughput,” “microfluidics,” and “microarray” capabilities, the company continuously develops medical products with independent intellectual property rights. It provides services for early cancer diagnosis and precision medicine research. Its “Tumor Hunter” technology, which employs peptide-coated magnetic nanoparticles to detect circulating tumor cells (CTCs) in peripheral blood, has received numerous domestic and international awards.

Novel Rapid Combined Diagnostic Product for Early Detection of Invasive Fungal Disease (IFD)

Dana (Tianjin) Biotechnology Co., Ltd.

Founded in March 2014 by Dr. Zhou Zeqi, a globally renowned expert in in vitro diagnostics (IVD), a leading talent in the Beijing-Tianjin-Hebei region, and an affiliate of Harvard Medical School, Dana Biotechnology was established with a registered capital of RMB 46 million. The company is dedicated to the research and development of new technologies for the early, rapid, and combined detection of invasive fungal diseases (IFD). It is the only company worldwide that proposes a combined detection solution and provides a complete portfolio of related products. Five of its products have obtained registration certificates from the China Food and Drug Administration (CFDA), and nine have received CE certification. Equipped with fully automated and semi-automated instruments for combined fungal detection, its solutions have been implemented in 120 key hospitals across China. Furthermore, the company has signed distribution agreements with 40 partners in 30 countries, demonstrating strong international competitiveness and significant growth potential.

Nohui

Hangzhou New Horizon Health Technology Co., Ltd.

New Horizon Launches "Changweiqing": An Internet-Plus Early Diagnosis and Treatment Technology for Colorectal CancerNew Horizon has introduced Changweiqing, an internet-plus early diagnosis and treatment solution for colorectal cancer. This innovative genetic testing technology is non-invasive, painless, and designed for at-home use. By analyzing fecal DNA, Changweiqing can detect precancerous colorectal lesions larger than 1 cm in diameter, identifying pathological changes up to five years earlier than routine health examinations. Changweiqing provides a simple and accessible solution for the early detection of colorectal cancer, and its widespread adoption has the potential to significantly reduce colorectal cancer mortality rates across China.

Handheld HbA1c Analyzer

Wuxi Bohuis Biopharmaceutical Technology Co., Ltd.

Wuxi Bohuis Biomedical Technology Co., Ltd., established in 2006, is among the first batch of “530” high-tech biomedical enterprises introduced to the Mashan National Life Science Park in Wuxi, Jiangsu Province. The company specializes in the research, development, and production of in vitro diagnostic technologies and products, providing rapid, accurate, simple, and reliable diagnostic solutions for public health. Bohuis currently holds patented technologies in more than 20 countries worldwide, and has launched three major product series—“Botangping,” “Huiankang,” and “Tai’ankang”—in the Chinese market, focusing on chronic diseases and obstetrics and gynecology.

Automated External Defibrillator (AED)

Jiuxin Medical Technology (Suzhou) Co., Ltd.

JiuXin Medical Technology (Suzhou) Co., Ltd. is committed to becoming a global professional provider of emergency resuscitation products and solutions. JiuXin Medical has developed a series of Automated External Defibrillators (AEDs), creating a comprehensive monitoring-treatment survival chain by applying remote management systems based on mobile internet technology and wearable vital signs monitoring systems for individual users. Through professional and reliable products and services, JiuXin Medical will provide safe life protection for cardiac patients.

Haiscare Liver Health Management Platform

Wuxi Hisky Medical Technology Co., Ltd.

Hiscan has developed FibroTouch, a non-invasive quantitative detection system for liver fibrosis based on transient elastography technology. This system overcomes the limitations of clinical liver biopsy and provides a new non-invasive, rapid, quantitative, and cost-effective solution for liver fibrosis assessment to China’s 280 million individuals with liver injury. Furthermore, by leveraging the device as a connectivity hub and integrating big data and mobile health technologies, it establishes a closed-loop data ecosystem among patients, devices, and physicians, thereby enabling effective management of chronic liver diseases. Positioned to address liver disease as a global public health challenge, the project offers solutions for early detection, early intervention, and early recovery from both hardware and data perspectives, serving the liver disease population and reducing societal costs.


Commentary: Internet Healthcare Needs “Partnerships”

Li Tiantian, founder and CEO of DXY, remarked during his project review, “The healthcare industry holds great promise, but it will not produce giants akin to BAT.” This is because the industry’s supply chain is excessively complex, making it difficult for any single company or service provider to cover the entire process and full value chain. “However, we can leverage partnerships to complement each other’s strengths, exploring commercial models and service innovations.”

At the final pitch session of the Medical Partner Competition, two oncology-related projects left a deep impression on Li Tiantian. “These two oncology projects are data-driven, enabling enhanced service integration and future scalability.” In addition, the handheld glycated hemoglobin (HbA1c) tester also made a significant impact on him. “The concept behind the HbA1c device is excellent, targeting a vast market. From a technical perspective, HbA1c is indeed a critical biomarker that plays a pivotal role in clinical decision-making.”

Li Tiantian believes that a viable business model is crucial for internet healthcare. Only through connections based on viable business models can the interests and needs of investment partners be satisfied. Whether it concerns oncology or glycated hemoglobin, true openness must be achieved by integrating processes across the upstream and downstream sectors.

Seizing the opportunity to provide commentary, Li Tiantian also expressed his expectations for the Healthcare Partner Competition. “When the next and subsequent editions of the Healthcare Partner Competition are launched, I hope we can engage in in-depth discussions on business models, such as how to better collaborate with other commercial partners.”

Li Tiantian stated, “The road ahead is long and will inevitably be fraught with challenges and obstacles, but we will join hands with our ‘partners’ to forge ahead toward a future that is more distant and full of hope.”